Purple Biotech Reports Second Quarter 2022 Financial Results
August 04, 2022 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Executive Leadership Changes
July 14, 2022 07:30 ET
|
Purple Biotech Ltd.
Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
May 27, 2022 07:15 ET
|
Purple Biotech Ltd.
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) --...
Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
May 18, 2022 08:18 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class,...
Purple Biotech Reports First Quarter 2022 Financial Results
May 12, 2022 08:13 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
April 11, 2022 07:37 ET
|
Purple Biotech Ltd.
First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC REHOVOT, Israel, April 11, 2022 (GLOBE NEWSWIRE)...
Purple Biotech Reports Second Half and Full-Year 2021 Financial Results
February 09, 2022 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Issues Letter to Shareholders
February 04, 2022 07:35 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
January 06, 2022 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
December 09, 2021 07:30 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...